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Abstract
Purpose Health-related quality of life (HRQOL) in differen-
tiated thyroid cancer (DTC) research has so far received little
attention and available results are conflicting. We studied the
HRQOL of radioiodine-naive DTC patients in comparison
with the general population (GP), investigated the course of
HRQOL up to 30 months after radioiodine remnant ablation
(RAA) and sought to identify patient characteristics associated
with HRQOL.
Methods We analysed data from routine HRQOL monitoring
at a nuclear medicine department. Between 2005 and 2013, a
total of 439 thyroid cancer patients (all histologies) completed
the EORTC Quality of Life Questionnaire Core-30 (QLQ-
C30) at least once during their treatment at the department.
We compared patients’ baseline HRQOL scores before RAA
with scores from age-matched and sex-matched controls from
the Austrian GP. We then determined the course of HRQOL
over the 30 months after RAA and assessed the impact of the
following clinical variables on HRQOL: method of thyroid-
stimulating hormone (TSH) stimulation, histology (papillary
vs. follicular) and disease stage.
Results A total of 284 patients (mean age 48.3 years, SD
15.0 years; 71.6 % women; 80.7 % papillary type) with a
baseline HRQOL assessment before RAA were available.
We found clinically meaningful differences in the detriment
in patients on almost all domains. These were largest for fa-
tigue (23 points) and role functioning (25 points). Data from
241 patients (mean age 48.6 years, SD 15.9 years; 68.9 %
women; 76.3 % papillary type) were included in the longitu-
dinal analysis. Investigating the course of HRQOL, a signifi-
cant improvement over time was found for role and emotional
functioning, fatigue, pain, and dyspnoea. A range of HRQOL
scores were improved in patients with exogenous TSH stim-
ulation, but some scores both in patients with exogenous TSH
stimulation and in those followed for 30 months, especially
fatigue and role functioning, did not reach levels in the GP
sample.
Conclusion Our results show that the favourable prognosis of
DTC does not directly translate into good HRQOL in these
patients. Persistent restrictions in regaining their normal daily
life in terms of work and leisure highlight the importance of
more detailed investigation of DTC patients’ wellbeing, sup-
port needs, and disease experience.
Keywords Differentiated thyroid cancer . Health-related
quality of life . Radioiodine remnant ablation
Introduction
In the context of differentiated thyroid cancer (DTC) the as-
sessment of patient-reported outcomes, including health-
related quality of life (HRQOL), as secondary treatment out-
comes has received attention only recently [1, 2]. A low inci-
dence rate of 6.3 per 100,000 per year and a low mortality rate
of 0.4 per 100,000 in Europe [3] might have impeded the
development of a scientific focus on DTC patients’ HRQOL.
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Thus, patient-reported information is scarce. Patients in clini-
cal practice often report that they have been told that they have
the Bgood^ cancer but that this does not reflect their personal
experience with the disease. Studies on long-term HRQOL in
DTC patients have shown conflicting results on how long
impairment persists beyond the window of active therapy
and when patients can expect to reach levels in the general
population (GP) again. For example, Schroeder et al. [4] state
that patients only experience minor quality of life impairment
as long as they do not have to undergo thyroxin withdrawal.
Others have found that thyroid cancer survivors still suffer
from a range of symptoms and functioning impairments
5 years and longer after diagnosis [5, 6]. Factors influencing
HRQOL in DTC patients and survivors have not been suffi-
ciently investigated. There is evidence that exogenous stimu-
lation with recombinant thyroid-stimulating hormone
(rhTSH) which facilitates the continued substitution of thyroid
hormones is able to prevent hypothyroid-related HRQOL im-
pairment [7–10]. However, for example morbidity and
HRQOL impairment as a consequence of life-long TSH sup-
pression therapy have not yet been investigated in detail, but
there is literature that suggests that they may be more preva-
lent than currently assumed [11–13].
During recent years, there has been growing recognition of
thyroid cancer patients’ demand for more medical information
on their disease and for more psychosocial support [10,
14–17]. Intensified research on HRQOL in this patient group,
including the use of cancer-specific HRQOL questionnaires,
and more longitudinally designed studies have been called for
[18]. The work presented here contributes new knowledge on
HRQOL in thyroid cancer patients by analysing longitudinal
data from HRQOL monitoring in clinical routine using the
widely used cancer-specific HRQOL instrument of the Euro-
pean Organization for Research and Treatment of Cancer
(EORTC), the Quality of Life Questionnaire-Core 30 (QLQ-
C30) [19]. In contrast to generic HRQOL instruments, which
have often been used to investigate thyroid cancer patients’
HRQOL, this questionnaire includes a range of problems ex-
perienced by most cancer patients, such as fatigue and pain. In
addition, such data collected outside the context of a clinical
study is able to provide interesting insights into HRQOL in
association with clinical factors, such as the method of TSH
stimulation in a routine setting.
Our objective was to explore DTC patients’HRQOL when
admitted for radioiodine remnant ablation (RAA) after thy-
roidectomy, radioiodine therapy (RAIT) and follow-up, and
to identify patient characteristic associated with HRQOL. The
two main aims were:
Aim 1 To compare DTC patients’ HRQOL profile on the
QLQ-C30 at the time of RAA with the profiles
of age-matched and sex-matched controls from
the GP.
Aim 2 To investigate DTC patients’ HRQOL trajectories
over a period of 30 months after RAA and to identify
patient characteristics associated with HRQOL.
Materials and methods
Samples and data collection
We retrospectively analysed data from HRQOLmonitoring in
DTC patients at the Department of Nuclear Medicine of the
Medical University of Innsbruck. According to Austrian law,
ethical approval is not required for retrospective analyses of
data collected for use in clinical routine.
Patients were treated with 131I. Dosages of 131I for RAA
were selected according to the results of radioiodine uptake
and diagnostic scans which were performed 4 weeks after
thyroidectomy (usually under endogenous stimulation of
TSH). Follow-up examinations, including the radioiodine up-
take and diagnostic scan, were performed at 6 and 12 months
after thyroidectomy (under endogenous or exogenous stimu-
lation of TSH), and thereafter once per year in patients without
further evidence of radioiodine-positive lesions. In patients
with radioiodine-positive lesions a follow-up examination in-
cluding the above-mentioned tests was performed 6 months
after each further RAIT.
Patients were invited to complete the QLQ-C30 at each
inpatient visit. From 2005 until 2011 HRQOL data were col-
lected on a paper and pencil basis and from 2011 with a
computer-based system using the software CHES
(Computer-based Health Evaluation System) [20].
Sociodemographic and clinical data were either directly en-
tered into the CHES system in case of electronic assessment or
collected from medical records for questionnaires from the
period of paper and pencil assessment.
General criteria for data to be included in the present anal-
ysis were:
& Histologically confirmed and 131I-sensitive DTC
& date of diagnosis not before 1 January 2005 (due to avail-
ability of electronic patient data)
Additional inclusion criterion for aim 1 was:
& Admission for RAA after thyroidectomy
Additional inclusion criteria for aim 2 were:
& Minimum two assessments per patient
& Assessments up to 30 months from diagnosis
The GP sample was drawn in 2002 by randomly selecting
2,000 persons from the official telephone directory. The
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response rate was 50.6 %. Representativeness was checked by
comparing the distribution of sociodemographic variables in
the sample with data from Statistics Austria. The same sample
was used for collecting reference data for the Functional As-
sessment of Cancer Therapy – General (FACT-G) and has
been described in detail in the respective publication [21].
Individuals from the GP sample (without cancer) were age-
matched and sex-matched to the DTC sample.
HRQOL questionnaire
HRQOL was assessed using the EORTC QLQ-C30 [19] as
not only is it the most widely used cancer-specific HRQOL
instrument in Europe, but was also expected to capture issues
relevant to thyroid cancer patients. It comprises 30 questions
building five functioning scales (physical, social, role, emo-
tional, cognitive), nine symptom scales (fatigue, nausea/
vomiting, pain, dyspnoea, sleep disturbances, appetite loss,
constipation, diarrhoea, and financial impact), and a scale for
global quality of life (QOL). Scoring was done according to
the QLQ-C30manual. Raw scores were transformed to a scale
of 0 – 100 with 100 reflecting the best score possible for
functioning scales and the worst score for symptom scales.
Statistical analysis
Patient characteristics and sampling bias Patient characteris-
tics are provided as mean and median percentages with stan-
dard deviations (SD) and interquartile ranges (IQR). As we
selected subsamples from a larger dataset of thyroid cancer
patients, the degree of selection bias was assessed by compar-
ing the patient characteristics with data from the Tyrolean
Tumour Registry [22]and comparing included and excluded
patients in terms of age, sex and clinical characteristics.
Analysis for aim 1 Analysis of variance was used to evaluate
differences in HRQOL between the DTC patients and the GP
sample. Variables included were group (DTC vs. GP), sex and
age. To assess if the effects of age and sex were disease-
specific or similar to age and sex differences in the GP, inter-
actions between group and age as well as group and sex were
investigated.
Analysis for aim 2 HRQOL trajectories and patient character-
istics associated with HRQOL were investigated using mixed
linear models due to their ability to handle unbalanced data.
This was necessary as we did not have HRQOL assessments
for all patients at all time points The domains of the QLQ-C30
were included as dependent variables. Age, sex and clinical
variables (histology, stage, method of TSH stimulation and
time since RAA) were included as independent variables
and first tested in univariate analysis. The number of cycles
of RAIT and the cumulative dose of 131I were not included as
they were time-dependent and confounded by the variable
time since RAA. Characteristics with a significant association
with HRQOL scores in univariate analyses were included in
multivariate models and excluded stepwise if they were no
longer significant. Interaction effects were investigated for
sex/age and clinical variables. In addition, we accounted for
correlations between assessments and included individual in-
tercepts as random factors.
Meaningful changes For the assessment of the clinical mean-
ingfulness of HRQOL differences, we referred to the standard
guidelines of Osoba et al. [23]. According to these guidelines,
a change of 5 – 10 % in the scale range can be perceived as a
meaningful change by a patient. For the scales of the QLQ-
C30, this results in defining a difference of 5 – 10 points as a
Bsmall^ difference, 10 – 20 points as a Bmoderate^ difference
and >20 points as a Blarge^ difference.
All statistical analyses were done using SPSS 21.0.
Results
Patient characteristics
The flow diagram in Fig. 1 shows the patient selection pro-
cess. Between January 2005 and September 2013, 439 thyroid
cancer (DTC and non-DTC) patients completed the HRQOL
questionnaire at least once. Altogether, these patients complet-
ed 1,390 assessments. Applying the criteria described in the
Statistical analysis section, 295 radioiodine-naive patients
were eligible for cross-sectional analysis in aim 1. At our
centre, patients usually undergo endogenous TSH stimulation
for RAA. Thus, only 11 of these 295 patients had exogenous
TSH stimulation for RAA. As this number was too small to be
included as a factor in the analyses, these 11 patients were
excluded, leaving 284 for comparison with the GP sample.
Their mean age was 48.3 years (SD 15.0 years) and 71.6 %
were women. Controls from the GP sample were age-matched
and sex-matched to the patient sample.
For the longitudinal analysis, 241 patients were eligible, i.e.
had completed the questionnaire at least twice. The mean age
of the patients was 48.6 years (SD 15.9 years), and 68.9 %
were women. The patient characteristics are shown in Table 1,
and the details of the 705 assessments performed in the 241
patients included in the longitudinal analysis are shown in
Table 2.
Assessment of sampling bias
The subsamples drawn for analysis appeared to be comparable
to the patients from the Tyrolean Tumour Registry concerning
sex (74 % vs. 72 % and 69% in our sample) and age (50 years
vs. 48 years in our samples). In addition, the numbers of
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patients in our subsamples diagnosed with localized disease
(76 % and 75 %) were comparable to numbers from the Ty-
rolean Tumour Registry (75 %). In our sample there were
more patients with distant disease (21 % and 22 %) than
among the patients from the Tyrolean Tumour Registry
(11 %). Information on histology could not be obtained from
the registry, but percentages for papillary type and follicular
type in our sample largely reflected the usual incidence pat-
terns for thyroid cancer (76 % papillary, 18 % follicular) [24].
Patients included in the longitudinal analysis were not differ-
ent from the excluded patients in terms of age (p=0.563), sex
(p=0.559) and stage (p=0.548). The samples differed in terms
of histology (p=0.002). For details see Table 1.
Aim 1: Comparison of DTC patients’ HRQOL with the GP
Comparisons of DTC patients before RAA with Austrian GP
scores showed that the patients’ HRQOL was significantly
worse (p<0.001 and p=0.014) on all domains except cognitive
functioning, diarrhoea and financial impact. Differences that
were statistically significant were also clinically meaningful
(≥5 points difference) except pain and nausea/vomiting. Large
differences were found for role functioning (25 points) and fa-
tigue (23 points). Moderate differences were found for sleep
disturbances (15 points), global QOL (15 points) and dyspnoea
(11 points). Differences for physical, social and emotional func-
tioning, appetite loss and constipation were small (7 – 10 points).
Fig. 1 Flow diagram of the patient selection process
Table 1 Patient characteristics
a The reasons for inclusion/
exclusion are shown in the
Statistical analysis section and the
flow diagram in Fig. 1
b p value is from the t-test or χ2 −
test for group comparisons
Characteristic Aim 1: cross-sectional
comparison








Age (years), mean±SD 48.3±15.0 48.6±15.9 47.8±13.0 0.563
Sex: female, n (%) 204 (71.6) 166 (68.9) 63 (68.4) 0.559
Histology, n (%)
Papillary 230 (80.7) 184 (76.3) 83 (91.2) 0.002
Follicular 55 (19.3) 57 (23.7) 9 (9.8)
Tumour stage, n (%)
I+II 217 (76.1) 181 (75.1) 72 (78.3) 0.548
III+IVa 60 (21.1) 53 (22.0) 18 (19.6)
Missing 8 (2.8) 7 (2.9) 2 (2.2)
Assessment method, n (%)
Paper and pencil 139 (48.8)
Computer-based 146 (51.2)
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To test if the influence of sex and age on HRQOL were
different in patients and the GP, interaction effects were also
considered in the comparison of the two groups. Significant
interactions between group and sex were found for role, social
and cognitive functioning as well as appetite loss. These
showed that on these domains female patients had significant-
ly more problems than male patients, while the difference
between men and women in the GP was only marginal (as
an example, see the interaction effect for appetite loss in
Fig. 2). Significant interactions between group and age were
found for social functioning, pain and appetite loss. The ef-
fects indicated that social functioning was decreased in pa-
tients but did not additionally decrease with age in the patient
group in contrast to the GP. For pain the curve of decline with
age was flatter in patients than in the GP and appetite loss
became less severe with age in patients, whereas it did not
show a relevant change in the GP (as an example, see the
interaction effect for appetite loss in Fig. 2).
Table 3 shows the marginal means for DTC patients and the
GP including impact of age and sex, and parameters for inter-
action effects for all domains.
Aim 2: Course of HRQOL in DTC patients
Variables with a significant association with HRQOL in mul-
tivariate models were time since RAA, disease stage and the
method of TSH stimulation (p values between 0.006 and
0.014). A change over time (over 30 months after RAA)
was found for role and emotional functioning, fatigue, pain
and dyspnoea. Despite variations between time-points (mostly
below or barely reaching the 5-point cut-off except for emo-
tional functioning) the changes were largely linear improve-
ments. The largest improvement between baseline and follow-
up at 30 months was found for pain (11 points). Role func-
tioning improved 9 points, emotional function 7 points, and
fatigue 8 points (see Fig. 3). Localized disease was associated
with better physical functioning only (7 point difference com-
pared with patients with distant disease). Exogenous TSH
stimulation was associated with better physical functioning
(6 points), role functioning (10 points), cognitive functioning
(8 points) and global QOL (10 points), and less fatigue (14
points), sleep disturbance (10 points) and appetite loss (11
points; Fig. 4).
While pain scores even fell below the level in the GP over
30 months after RAA, role functioning, fatigue, and dyspnoea
scores remained clearly below the level in the GP (defined as a
Fig. 2 Interaction between
patient samples (GP vs. DTC
patients) and sex and age for
appetite loss
Table 2 Details of 705 assessments performed in the 241 patients
included in the longitudinal analysis
Assessments Value
Time since diagnosis (months), mean±SD 13.3±11.6
Number of RAIT cycles, median (IQR)a 1.0 (1.0)







Admission reason, n (%)
Therapy 261 (37.0)
Follow-up 444 (63.0)




Assessment method, n (%)
Paper and pencil 424 (60.1)
Computer-based 281 (39.9)
a Therapeutic doses 3.7 and 7.4 GBq
b 41 patients with 46 assessments
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maximum difference of 5 points) during the entire assessment
period, also under exogenous TSH stimulation.
Table 4 shows sex-adjusted and age-adjusted marginal
means for clinical subgroups.
Discussion
In the present investigation we analysed the HRQOL of DTC
patients after thyroidectomy undergoing RAA and RAIT and
during follow-up using data from HRQOLmonitoring in clin-
ical routine. Such data have so far been scarce and provide
valuable additional information to findings from clinical
studies.
In a cross-sectional study we compared HRQOL scores in
DTC patients at the time of their RAA with scores in the
Austrian GP. In addition, we analysed longitudinal data up
to 30 months after RAA and investigated the effects of histol-
ogy (papillary vs. follicular), disease stage, method of TSH
stimulation and time since RAA on HRQOL scores. The
Table 3 Sex-adjusted and age-adjusted marginal means for patients and the GP with 95 % confidence intervals and parameters for interaction effects
Domain Marginal means (95 % CI) Interactions effects
Patients General population Mean differencea p value Sample × sexb p value Sample × agec p value
Physical functioningd 82 (81 – 84) 90 (88 – 92) 8 <0.001
Role functioning 62 (59 – 66) 87 (83 – 90) 25 <0.001 −11 0.033
Social functioning 73 (70 – 77) 84 (81 – 87) 9 0.001 −11 0.026 0.33 0.026
Emotional functioninge 63 (60 – 66) 72 (69 – 75) 9 <0.001
Cognitive functioninge,d 80 (77 – 83) 83 (80 – 86) 3 0.138 −10 0.017
Global QOLd 61 (58 – 64) 76 (74 – 79) 15 <0.001
Fatiguee 45 (2 – 47) 22 (19 – 25) 23 <0.001
Nausea/vomiting 7 (5 – 9) 4 (3 – 6) 3 0.013
Paind 22 (18 – 25) 20 (17 – 23) 2 0.014 −0.33 0.017
Dyspnoead 22 (20 – 25) 9 (7 – 12) 11 <0.001
Sleep disturbanced 39 (36 – 43) 24 (21 – 27) 15 <0.001
Appetite losse 16 (13 – 19) 6 (4 – 9) 10 <0.001 8.7 0.040 −0.28 0.033
Constipatione 15 (12 – 18) 8 (5 – 11) 7 0.001
Diarrhoeae 8 (5 – 10) 9 (7 – 11) 1 0.532
Financial impactd 12 (9 – 15) 10 (7 – 12) 2 0.335
a Clinically meaningful differences in bold type
b Reference group: male
cReference group: patient
dMain effect of age worse scores with increasing age (p≤0.030):
e Significant main effect of sex worse scores in women (p≤0.007):
Fig. 3 Scales with significant
changes over time (adjusted for
effects of age, sex and method of
TSH stimulation)
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cumulative dose of 131I has shown to be a clinical predictor of
HRQOL [25] but could not be included into our multivariate
models as it was highly confounded by time frombaseline. Thus,
the effects of time since RAA could very well be attributable to
this clinical variable, but statistically could not be assigned to
either of them due to collinearity. In all analyses we adjusted for
the effects of age and sex, i.e. the effects we found cannot be
explained by the facts that women usually report worse HRQOL
and that the majority of DTC patients are women.
In the cross-sectional comparison of HRQOL scores in
DTC patients and the scores in the GP, patients reported worse
HRQOL on almost all domains of the QLQ-C30. In particular,
large differences were found for role functioning (25 points;
comprising questions on the ability to perform usual work and
leisure activities), fatigue (23 points), sleep disturbance (15
points), and global QOL (15 points; comprising questions on
subjective global health state and QOL). Against our expecta-
tions from clinical experience, there was no overall impair-
ment of cognitive functioning in patients. However, there
was a significant difference in cognitive functioning between
DTC patients and the GP, but in women only. A similar inter-
action effect was found for role functioning and social func-
tioning (comprising questions on ability to participate in social
activities and fulfil social roles) and appetite loss.
Fig. 4 Scales with a significant
impact of method of TSH
stimulation
Table 4 Marginal means for
clinical subgroups with
significant score differences
a Adjusted for impact of sex:
worse scores in women
(p≤0.021)
b Adjusted for impact of age:
worse scores with increasing age
(p≤0.025)
c Adjusted for time since
diagnosis (p≤0.01)
d Adjusted for assessment method
and its interaction with age
(p=0.001)
Domain Marginal means (95 % CI)
Method of TSH stimulation Stage
Endogenous Exogenous Localized Distant
Physical functioninga,b 82 (78 – 85) 88 (83 – 92) 88 (82 – 92) 81 (79 – 85)
Role functioningc 70 (66 – 73) 80 (71 – 88)
Social functioninga 78 (75 – 81) 86 (79 – 93)
Emotional functioninga,c
Cognitive functioningd 74 (71 – 77) 83 (76 – 90)
Global QOL 62 (60 – 65) 72 (65 – 78)




Sleep disturbancea,b,c 36 (32 – 40) 26 (17 – 35)
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These results were not surprising insofar as all of our DTC
patients in this treatment phase were in a hypothyroid state. It
is well known that hypothyroidism causes a broad range of
physical as well as psychological symptoms, such as consti-
pation, weight gain, fatigue, depression and slowed cognition,
and that associated distress is high [26, 27]. However, the
magnitude of the effect was still striking as it is comparable
to that in other cancer diagnoses which are usually considered
much more impairing, such as laryngeal cancer [28]. Further-
more, our longitudinal analyses indicated that some issues
were influenced by a hypothyroid state to the extent we had
expected. Emotional functioning (comprising feelings of wor-
ry, anxiousness, nervousness and irritability) in our sample
had improved to the level in the GP (defined as a difference
<5 points) after 12 months, had worsened at 24 months, and
had recovered again at 30 months, but without significant
effect of the method of TSH stimulation. Similar fluctuations
over time were observed for fatigue scores, which were sig-
nificantly lower under exogenous TSH stimulation but with-
out reaching the level in the GP level during the observation
period. Likewise, role functioning did not reach the level in
the GP level either over time or under exogenous TSH stim-
ulation. However, in line with previous reports that exogenous
TSH stimulation is associated with better HRQOL especially
with regard to functioning (physical, social, role and emotion-
al), sleep disturbance and fatigue [8, 29], our patients with
endogenous TSH stimulation were also at risk of lowHRQOL
(on the domains physical, role, social and cognitive function-
ing, global QOL, fatigue, sleep disturbance and appetite loss).
Yet the conclusion that HRQOL impairment is minor in DTC
patients as long as they do not have to undergo hormone
withdrawal [4] cannot be supported by the present data.
There are conflicting reports in the literature as to when a
restored HRQOL can be expected. For example, Taieb et al.
found that HROQL is restored shortly after surgery [30] and
Crevenna et al. found significant improvements at 1 year after
diagnosis and beyond [5]. Our results, on the one hand,
showed significant improvements after 12 months for some
domains. On the other hand, they also support reports of
prolonged posttreatment fatigue in thyroid cancer patients
and survivors [31]. Physiological explanations discussed are
related to TSH suppression during posttreatment care. Fatigue
might be a result of subclinical hyperthyroidism [32] which
again possibly causes a permanent change in the autonomic
nervous system [33]. It has also been suggested that the opti-
mal preoperative TSH level might be different from the target
value of TSH suppressive therapy [34]. Husson et al. found
that fatigue in short-term and long-term survivors of thyroid
cancer is strongly associated with thyroid-specific HRQOL,
including sympathetic problems and emotional distress [35].
Our own data showed similar courses of fatigue and emotional
distress over time. These results suggest that, aside from iden-
tifying physiological causes, the emotional aspect of fatigue
might require more attention in the management of thyroid
cancer patients as psychological copingmechanismsmay play
an important role here.
Our results on the comparison of patient scores and scores
from the GP are largely in line with the results from a previous
study on HRQOL in thyroid cancer patients during inpatient
rehabilitation conducted in Germany [15]. The German study
clearly showed larger differences between patients and the GP
on QLQ-C30 domains. The scores differed from our data by
>5 points, except for global QOL, nausea/vomiting, appetite
loss, constipation and diarrhoea. In particular, cognitive and
emotional problems, pain and financial difficulties were more
pronounced in the German patient group (the scores differed
from our data by ≥19 points). The fact that patients with higher
disease burden are more likely to make use of inpatient reha-
bilitation could be one explanation for these large differences.
In addition, rehabilitation prolongs absenteeism from work
which might cause additional financial strain. It is also not
unusual that psychosocial distress in particular is aggravated
directly after completion of active therapy.
The impact of sex and age found in our sample is in line
with previous reports [5, 15, 25, 36], as we also found more
impairment in women than in men and decreasing scores with
increasing age on a range of domains. Most of these effects
were not disease-specific, but rather reflected sex and age
differences that can also be observed in the GP. This is an
important issue when interpreting such effects in patient sam-
ples [37]. In addition, disease-specific patterns of the impact
of age were found for social functioning, pain and appetite
loss. While scores in patients were significantly worse, their
decline with age was less pronounced than in the GP.
Despite that the fact that our results were inherently con-
sistent and bias assessment did not cause severe concern, the
present analysis had some limitations that restrict the general-
ization of the findings. Firstly, in our samples the number of
patients with follicular cancer type was about 10 % higher
than in the GP. We did not, however, find an effect of histol-
ogy in multivariate analysis, indicating that other factors were
more strongly associated with HRQOL. Secondly, the number
of patients in the monitoring programme decreased with time,
and thus the results may have been biased by the selection of
patients. However, there was no significant difference in stage
of disease between earlier and later assessment time-points,
and the majority of patients at the 30-month follow-up had
received one or two cycles of RAIT. Thus, there is no indica-
tion that patients with more severe disease participated longer
in HRQOL monitoring. Thirdly, there was an unbalanced dis-
tribution of assessments with exogenous and endogenous
TSH stimulation which limited the validity of the results of
comparisons between the two methods. Therefore, analyses
including this factor were rerun but resulted in only minor
changes in the remaining model parameters (results not
shown).
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Fourthly, the distribution of paper and pencil assessments
and of electronic assessments suggest more missing data dur-
ing the period of paper and pencil assessment. Therefore, we
investigated the influence of the assessment method on
HRQOL scores and found that older patients scored worse
on cognitive functioning when assessed using the computer-
based system (8 points difference). This finding may indicate
some selection bias. A plausible explanation seems to be that
the inclusion of patients in the HRQOL monitoring pro-
gramme might have been affected by subjective factors. Clin-
ical personnel who, since electronic assessment can immedi-
ately access a patient’s HRQOL scores and the information
can be used in the communication with the patient, might have
become increasingly motivated to include as many patients as
possible. In addition, presentation of questions on a tablet
computer might be advantageous for cognitively impaired pa-
tients as there are usually only two or three questions per page
in a large font. Detailed analysis on the impact of assessment
method on cognitive functioning in the entire monitoring sam-
ple is warranted.
It has also to be kept in mind that our Austrian reference
data were collected in 2002 and values may have changed in
the meantime. Also we cannot provide information on possi-
ble differences between Tyrolean and Austrian GP values,
which if they do exist, would results in either overestimation
or underestimation of thyroid cancer patients’ HRQOL im-
pairment. Our reference values were, however, consistent with
the EORTC QLQ reference values for the GP published in
2008 [38] and, thus, seem to be sufficiently sensitive. In ad-
dition, in a recent update of the German reference values for
the QLQ-C30 from the year 2001 changes were small and not
clinically relevant for most scales, except for fatigue, sleep
disturbances and pain. These symptoms were more severe in
the new GP sample, which according to the authors, may be
attributed to a sampling bias [39].
In conclusion, our results provide further evidence that
DTC patients’ burden from symptoms and functioning im-
pairments is unrelated to the favourable clinical outcome.
Nonetheless, thyroid cancer is still often labelled as the
Bgood^ cancer with only minor impairments so that patients
may feel that their concerns are being trivialized and that they
lack information and support [16, 40]. Psychosocial distress as
well as persistent problems with fatigue and possibly resulting
difficulties at work and during leisure time are frequently
overlooked in clinical practice and often falsely attributed to
hypothyroidism only. Thyroid cancer patients with HRQOL
impairments which persist quite some time after treatment are
not uncommon. This is important information for treating
physicians, especially as the Baverage^ thyroid cancer patient
is usually seen by representatives of a range of different med-
ical professions and there is rarely continuity of care during
the treatment and follow-up process. Acknowledging thyroid
cancer patients’ burden is essential in improving their care,
especially when it comes to psychosocial issues. Finally, our
results highlight the need for more systematic investigations
of DTC patients HRQOL in order to provide patients with
reliable information about what they need to expect when
living with a DTC diagnosis and the sequelae of treatment.
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